PMID- 24274357 OWN - NLM STAT- MEDLINE DCOM- 20160219 LR - 20211021 IS - 1751-7893 (Electronic) IS - 1751-7885 (Print) IS - 1751-7885 (Linking) VI - 9 IP - 3 DP - 2015 Jun TI - Reasons for cannabis use among youths at ultra high risk for psychosis. PG - 207-10 LID - 10.1111/eip.12112 [doi] AB - AIM: Cannabis use is prevalent in schizophrenia and its risk states, despite its association with anxiety and positive symptoms. While schizophrenia patients report using cannabis for mood enhancement and social motives, it is not known what motivates clinical high risk (CHR) patients to use cannabis. METHODS: Among 102 CHR patients, 24 (23%) endorsed cannabis use, and were queried as to reasons for use, using a scale previously administered in schizophrenia patients. We hypothesized a primary motivation for mood enhancement related to anhedonia. We evaluated the 'self-medication' hypothesis by examining if motivation for symptom relief was associated with concurrent severity of symptoms. RESULTS: The rank order of reasons for use in CHR patients was similar to that previously reported by schizophrenia patients, with mood enhancement and social motives as primary reasons for use, and the motivation to use cannabis for symptom relief comparatively less common. Motivation for mood enhancement had a trend association with anhedonia. Motivation for symptom relief was entirely unrelated to concurrent severity of positive and anxiety symptoms. CONCLUSION: As in schizophrenia, CHR patients primarily use cannabis for mood enhancement, especially in the context of decreased motivation to seek pleasure otherwise. Negative symptoms may drive cannabis use in schizophrenia and its risk states, which may exacerbate positive symptoms. By contrast, CHR patients do not report using cannabis to 'self-medicate' emergent positive symptoms. The understanding of motives for cannabis use among CHR patients may be informative for treatments aimed at reducing use, such as motivational interviewing. CI - (c) 2013 Wiley Publishing Asia Pty Ltd. FAU - Gill, Kelly E AU - Gill KE AD - Columbia University, Department of Psychiatry, New York State Psychiatric Institute, New York, New York, USA. FAU - Poe, Lucy AU - Poe L FAU - Azimov, Neyra AU - Azimov N FAU - Ben-David, Shelly AU - Ben-David S FAU - Vadhan, Nehal P AU - Vadhan NP FAU - Girgis, Ragy AU - Girgis R FAU - Moore, Holly AU - Moore H FAU - Cressman, Victoria AU - Cressman V FAU - Corcoran, Cheryl M AU - Corcoran CM LA - eng GR - K23MH066279/MH/NIMH NIH HHS/United States GR - UL1 RR024156/RR/NCRR NIH HHS/United States GR - K23 MH066279/MH/NIMH NIH HHS/United States GR - KL2 TR001874/TR/NCATS NIH HHS/United States GR - RC1 MH088740/MH/NIMH NIH HHS/United States GR - UL1 TR000040/TR/NCATS NIH HHS/United States GR - R21 MH086125/MH/NIMH NIH HHS/United States GR - R21MH086125-02/MH/NIMH NIH HHS/United States GR - R01093398-02/PHS HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20131126 PL - Australia TA - Early Interv Psychiatry JT - Early intervention in psychiatry JID - 101320027 SB - IM MH - Female MH - Humans MH - Male MH - Marijuana Smoking/*psychology MH - *Motivation MH - Prodromal Symptoms MH - Psychotic Disorders/*psychology MH - Risk MH - Self Medication/*psychology MH - Young Adult PMC - PMC4033707 MID - NIHMS542497 OTO - NOTNLM OT - anhedonia OT - cannabis OT - motivation OT - prodromal OT - psychosis OT - schizophrenia EDAT- 2013/11/28 06:00 MHDA- 2016/02/20 06:00 PMCR- 2016/06/01 CRDT- 2013/11/27 06:00 PHST- 2013/07/20 00:00 [received] PHST- 2013/10/26 00:00 [accepted] PHST- 2013/11/27 06:00 [entrez] PHST- 2013/11/28 06:00 [pubmed] PHST- 2016/02/20 06:00 [medline] PHST- 2016/06/01 00:00 [pmc-release] AID - 10.1111/eip.12112 [doi] PST - ppublish SO - Early Interv Psychiatry. 2015 Jun;9(3):207-10. doi: 10.1111/eip.12112. Epub 2013 Nov 26.